ENPP2 and liver disorder: Moreover, inhibition by PF8380 in CCl4‐induced liver disease models has shown to reduce plasma ATX activity and liver LPA levels by approximately 50%, and attenuate fibrosis‐based on histopathological scoring and collagen deposition in the liver (Kaffe et al, 2017).